Article Text

Download PDFPDF

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
  1. Jessica Spahn1,
  2. Jing Peng1,
  3. Edward Lorenzana1,
  4. David Kan1,
  5. Thomas Hunsaker1,
  6. Ehud Segal1,
  7. Mario Mautino2,
  8. Erik Brincks2,
  9. Andrea Pirzkall1,
  10. Sean Kelley1,
  11. Sami Mahrus1,
  12. Liling Liu1,
  13. Stephanie Dale1,
  14. Cristine Quiason1,
  15. Elizabeth Jones1,
  16. Yichin Liu1,
  17. Sheerin Latham1,
  18. Laurent Salphati1,
  19. Kevin DeMent1,
  20. Mark Merchant1 and
  21. Georgia Hatzivassiliou1
  1. Aff1 grid.418158.10000000405344718Genentech South San Francisco CA USA
  2. Aff2 grid.426927.cNewLink Genetics, Inc. Ames IA USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Indoleamine 2, 3-dioxygenase (IDO1) is a cytosolic enzyme catalyzing the oxidation of tryptophan to kynurenine. IDO1 plays an important role in modulating immune responses in cancer, where increasing evidence suggests that IDO1 expression by dendritic cells (DCs) and other antigen-presenting cells (APCs) contributes to tumor-mediated immune suppression. Programmed death-ligand 1 (PD-L1) is a cell surface protein that is broadly expressed by tumor cells and tumor-infiltrating immune cells in many human cancers. Blockade of PD-L1 or PD-1 with monoclonal antibodies results in strong and often rapid anti-tumor effects in preclinical models and in the clinic, where deep and durable objective responses have been observed in a number of tumor types including melanoma, NSCLC, renal and bladder cancer. Accumulating preclinical and clinical data provide evidence that host immunosuppression by tumor cells is mediated by multiple pathways, and therefore combination therapy regimens employing one or more targeted immunotherapy agents are necessary for more complete and durable patient responses. The combination of IDO1 inhibition with PD-L1 blockade has strong rationale since both checkpoints are co-expressed in many cancers and inhibit immune responses via complementary mechanisms. Using mouse syngeneic tumor models we present further evidence of the therapeutic potential of combining IDO1 inhibition with anti-PD-L1 blockade. We observe improved depth and duration of responses in mice treated with the combination regimen versus anti-PD-L1 blockade alone. These studies also reveal potential immunomodulatory effects responsible for the observed efficacy, namely an improved CD8:Treg ratio and evidence of increased maturation and antigen presentation capacity by DCs and APCs in the combination arm. Clinical trials will further assess the potential of this promising combination regimen in patients. A Phase Ib, open-label, multicenter, global study is underway to evaluate the safety, tolerability, and pharmacokinetics of the combination of GDC-0919 and atezolizumab (MPDL3280A, anti-PD-L1) in patients with locally advanced or metastatic incurable solid tumors (NCT02471846).